← Back to Clinical Trials
Recruiting NCT07642674

NCT07642674 The Effect of Intravenous Dexketoprofen on the Severity and Incidence of Rebound Pain

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07642674
Status Recruiting
Phase
Sponsor Eskisehir Osmangazi University
Condition Postoperative Pain
Study Type INTERVENTIONAL
Enrollment 66 participants
Start Date 2026-06-11
Primary Completion 2027-01-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 70 Years
Study Type INTERVENTIONAL
Interventions
ISB + paracetamol IV 3*1ISB+ paracetamol IV 3*1 +deksketoprofen IV 2*1

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 66 participants in total. It began in 2026-06-11 with a primary completion date of 2027-01-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Orthopedic shoulder surgeries are associated with severe postoperative pain, particularly within the first 24-48 hours after surgery. In postoperative pain management, single or continue interscalene brachial plexus blocks, acetaminophen, nonsteroidal anti-inflammatory drugs (NSAIDs), and opioids administered as needed are commonly used as components of multimodal analgesia. Rebound pain is defined as severe postoperative pain (VAS ≥ 7) occurring within the first 24 hours after resolution of the block. It is considered an adverse effect of regional anesthesia and typically develops 8-12 hours after a single-shot nerve block. Risk factors for rebound pain include pre-existing pain, female sex, younger age, bone surgery, lack of intraoperative dexamethasone administration, and inadequate analgesia. The primary objective of this study is to evaluate the effect of intravenous dexketoprofen administered during the postoperative period on the incidence and severity of rebound pain in patients undergoing shoulder surgery with interscalene brachial plexus block

Eligibility Criteria

Inclusion Criteria: Age 18-70 years ASA score of I-III Arthroscopic shoulder surgery Exclusion Criteria: Patients who do not wish to participate in the study Creatinine clearance \<50 mL/ min Patients for whom NSAID use is contraindicated due to heart failure, Patients with psychiatric or cognitive dysfunction that would impair their ability to assess visual analog scale (VAS) pain scores Patients for whom peripheral nerve block is contraindicated

Contact & Investigator

Central Contact

Çağla Uzalp

✉ caglauzalp@gmail.com

📞 02222392979

Principal Investigator

MERYEM ONAY

STUDY CHAIR

Eskisehir Osmangazi University Faculty Of Medıcıne

Frequently Asked Questions

Who can join the NCT07642674 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Postoperative Pain. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07642674 currently recruiting?

Yes, NCT07642674 is actively recruiting participants. Contact the research team at caglauzalp@gmail.com for enrollment information.

Where is the NCT07642674 trial being conducted?

This trial is being conducted at Eskişehir, Turkey (Türkiye).

Who is sponsoring the NCT07642674 clinical trial?

NCT07642674 is sponsored by Eskisehir Osmangazi University. The principal investigator is MERYEM ONAY at Eskisehir Osmangazi University Faculty Of Medıcıne. The trial plans to enroll 66 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology